ChemAxon Announces new CEO and Head of R&D
News May 13, 2008
ChemAxon, a software solutions provider for cheminformatics, has announced the appointment of Alex Drijver as CEO. The arrival signals the companies increased focus on business development and market position.
Ferenc Csizmadia, founder and former CEO, moves to Chairman and Head of Research and Development. The new R&D position formalizes the bridge between the customer base and the company’s development strategy and in particular the next generation of products under launch.
Alex joins ChemAxon with over 20 years international commercial experience, most recently as CEO and CFO of ThalesNano Inc, a Budapest based manufacturer of novel microfluidic based instruments for chemical synthesis, and CFO of ComGenex, Inc., a chemistry services provider now part of Albany Molecular.
New Chemical Synthesis Process: Synergy of Two Catalysts in One FlaskNews
Researchers report the one-step synthesis of a ketone from an aldehyde by the combination of thiazolium N-heterocyclic carbene and palladium/bisphosphine catalysts in one flask. The two catalysts function in a synergistic manner. This study is expected to lead to new synthesis processes of precursor compounds for medications.READ MORE
Synthesis of Drug-Like Molecules Simplified Using New Cross-Coupling MethodNews
Researchers have designed a new molecule-building method. The technique, described recently in the journal Science, paves the way toward other new chemical reactions and facilitates the synthesis of pharmaceutically-relevant molecules.READ MORE
Domainex Appoints Dr Bodo Spori as Head of Business Development for EuropeNews
Domainex Ltd, a privately-owned drug discovery services company, is pleased to announce the appointment of Dr Bodo Spori as Head of Business Development for Europe.READ MORE